<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methylene blue: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methylene blue: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methylene blue: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11814" href="/d/html/11814.html" rel="external">see "Methylene blue: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12599" href="/d/html/12599.html" rel="external">see "Methylene blue: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F46732338"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome with concomitant use of serotonergic drugs and opioids:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methylene blue may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. Avoid concomitant use of methylene blue with selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, and opioids.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F48875150"><span class="drugH1">Brand Names: US</span>
<ul>
<li>ProvayBlue</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F195174"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote;</li>
<li>
                        Phenothiazine Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F195166"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f719870-6865-4be5-a2a5-f7c43ffa35d4">Chromoendoscopy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chromoendoscopy (off-label use):</b>
<b>Topical:</b> 0.1% to 1% solution sprayed via catheter or directly applied onto GI mucosa during procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18178207','lexi-content-ref-24016362','lexi-content-ref-24639382','lexi-content-ref-12671882','lexi-content-ref-17383417','lexi-content-ref-19215918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18178207','lexi-content-ref-24016362','lexi-content-ref-24639382','lexi-content-ref-12671882','lexi-content-ref-17383417','lexi-content-ref-19215918'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b412cfa8-b2e0-4e7c-a020-5ef52e0b3a68">Ifosfamide-induced encephalopathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ifosfamide-induced encephalopathy (off-label use):</b>
<b>Note:</b> Treatment may not be necessary; encephalopathy may improve spontaneously (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16391008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16391008'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment: <b>Oral, IV:</b> 50 mg as a single dose or every 4 to 8 hours until symptoms resolve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16391008','lexi-content-ref-14570094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16391008','lexi-content-ref-14570094'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Prophylaxis (secondary): <b>Oral, IV:</b> 50 mg every 6 to 8 hours; <b>Note:</b> Prophylaxis has been described as beginning on the day prior to or on the day of subsequent courses of ifosfamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16391008','lexi-content-ref-14570094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16391008','lexi-content-ref-14570094'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d7dfeb0b-9114-460b-a831-68b6660e598d">Methemoglobinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methemoglobinemia (acquired):</b>
<b>IV:</b> 1 to 2 mg/kg over 5 to 30 minutes (maximum single dose: 100 mg, using actual body weight; however, maximum dose has not been established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.2','lexi-content-ref-26108709']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.2','lexi-content-ref-26108709'])">Ref</a></span>)); may repeat dose 1 hour later if methemoglobin level remains above 30% or symptoms persist.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If resolution does not occur after 2 doses, consider alternative therapy and consulting with a poison control center, as high doses may result in hemolysis or paradoxical methemoglobinemia, especially in patients with glucose-6-phosphate dehydrogenase deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9605379','lexi-content-ref-Howland.2','lexi-content-ref-28078984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9605379','lexi-content-ref-Howland.2','lexi-content-ref-28078984'])">Ref</a></span>). Repeat dosing may be required in patients who have ingested a long-acting oxidant drug or toxin (eg, dapsone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64502832-afb2-4634-b4cc-9964152e6c0b">Onychomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Onychomycosis (off-label use):</b>
<b>Topical:</b> 2% solution applied to affected area(s) at ~2-week intervals for 4 to 6 months; used in conjunction with photodynamic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32890444','lexi-content-ref-30168611','lexi-content-ref-24474123','lexi-content-ref-24502311','lexi-content-ref-24626676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32890444','lexi-content-ref-30168611','lexi-content-ref-24474123','lexi-content-ref-24502311','lexi-content-ref-24626676'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb88f1de-8767-46f9-ae47-7f1df55651b8">Sentinel node mapping in breast cancer surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sentinel node mapping in breast cancer surgery (off-label use):</b>
<b>Intraparenchymal:</b> 5 mL of a 1% solution injected in a subareolar or peritumoral area once during procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28173818','lexi-content-ref-16958960','lexi-content-ref-21360537','lexi-content-ref-11469932','lexi-content-ref-12679308','lexi-content-ref-15720998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28173818','lexi-content-ref-16958960','lexi-content-ref-21360537','lexi-content-ref-11469932','lexi-content-ref-12679308','lexi-content-ref-15720998'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dbc3d915-e72b-4ff0-a55d-9b30bb0869da">Septic shock or other vasodilatory shock states</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic shock or other vasodilatory shock states </b>
<b>(adjunctive agent): Note: </b>May consider in patients with refractory shock or salvage therapy (ie, nonresponsive to fluid therapy and standard vasopressors). Routine use is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36915146','lexi-content-ref-11588440','lexi-content-ref-35761204','lexi-content-ref-32020043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36915146','lexi-content-ref-11588440','lexi-content-ref-35761204','lexi-content-ref-32020043'])">Ref</a></span>). Optimal dose and regimens are uncertain; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1 to 2 mg/kg once daily for up to 3 doses, if needed; administer over 15 minutes to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36915146','lexi-content-ref-11588440','lexi-content-ref-35761204','lexi-content-ref-32020043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36915146','lexi-content-ref-11588440','lexi-content-ref-35761204','lexi-content-ref-32020043'])">Ref</a></span>). Some have employed a continuous infusion (0.25 to 2 mg/kg/hour for up to 48 hours) after administration of the initial bolus dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32435102','lexi-content-ref-11588440','lexi-content-ref-36705345','lexi-content-ref-35761204','lexi-content-ref-36237547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32435102','lexi-content-ref-11588440','lexi-content-ref-36705345','lexi-content-ref-35761204','lexi-content-ref-36237547'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="23d2cbbc-ff3f-4386-9748-a67ea656c31b">Shock, beta-blocker or calcium channel blocker overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Shock, beta-blocker or calcium channel blocker overdose (off-label use): Note: </b>Dose based on use in vasoplegia syndrome associated with cardiac surgery:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 to 2 mg/kg over 20 to 60 minutes administered once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30606508','lexi-content-ref-14759425','lexi-content-ref-12830064']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30606508','lexi-content-ref-14759425','lexi-content-ref-12830064'])">Ref</a></span>).<b> Note:</b> Improvement of shock (eg, increased systemic vascular resistance, reduced vasopressor dosage) has been observed within 1 to 2 hours following methylene blue administration. Some have employed the use of continuous infusion (0.5 to 1 mg/kg/hour) after administration of the bolus dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23334490','lexi-content-ref-21546119','lexi-content-ref-28551045','lexi-content-ref-25247756','lexi-content-ref-23972738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23334490','lexi-content-ref-21546119','lexi-content-ref-28551045','lexi-content-ref-25247756','lexi-content-ref-23972738'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa777a5c-c651-4ccf-aa79-e58f9718b130">Vasoplegia syndrome associated with cardiac surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasoplegia syndrome associated with cardiac surgery (off-label use):</b>
<b>IV: </b>1 to 2 mg/kg over 20 to 60 minutes administered once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30606508','lexi-content-ref-14759425','lexi-content-ref-12830064']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30606508','lexi-content-ref-14759425','lexi-content-ref-12830064'])">Ref</a></span>). If administered during cardiopulmonary bypass, may consider a higher dose (2 to 3 mg/kg) due to increased V<sub>d</sub> during bypass (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16790616','lexi-content-ref-31917073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16790616','lexi-content-ref-31917073'])">Ref</a></span>). <b>Note:</b> Improvement of vasoplegia (eg, increased systemic vascular resistance, reduced vasopressor dosage) has been observed within 1 to 2 hours following methylene blue administration. Some have employed the use of continuous infusion (0.5 to 1 mg/kg/hour) after administration of the bolus dose; however, prospective clinical trials are necessary to validate this dosing schema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28551045','lexi-content-ref-25247756','lexi-content-ref-23972738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28551045','lexi-content-ref-25247756','lexi-content-ref-23972738'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991614"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;">Generic: There are no dosage adjustments provided in the manufacturer's labeling. However, use with caution in severe renal impairment.</p>
<p style="text-indent:0em;">ProvayBlue:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 60 to 80 mL/min/1.73 m<sup>2</sup>: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 15 to 59 mL/min/1.73 m<sup>2</sup>: 1 mg/kg as a single dose; consider alternative treatment if methemoglobin level remains &gt;30% or if clinical symptoms persist 1 hour after dosing.</p></div>
<div class="block doha drugH1Div" id="F50988846"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, methylene blue is extensively metabolized in the liver. Monitor for toxicities for an extended period of time following methylene blue treatment in patients with hepatic impairment.</p></div>
<div class="block dot drugH1Div" id="F58836149"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hemolysis, severe: Discontinue and consider alternative treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin syndrome: Discontinue treatment and initiate supportive treatment if signs/symptoms arise.</p></div>
<div class="block doe drugH1Div" id="F195167"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F195170"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12599" href="/d/html/12599.html" rel="external">see "Methylene blue: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Products are available in multiple concentrations (0.5% and 1%); use extra precaution when calculating dose volumes.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="146f927b-4a39-437d-8e83-062a642e0ab7">Methemoglobinemia, acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methemoglobinemia, acquired (including drug-induced)</b>
<b>: </b>Infants, Children, and Adolescents: I.O., IV: 1 to 2 mg/kg may be repeated every 30 to 60 minutes if necessary (eg, methemoglobin level &gt;30% or signs and symptoms persist) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>); consider alternative treatment if no resolution after 2 doses. Intraosseous administration has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9867898','lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9867898','lexi-content-ref-Howland.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51129928"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution in patients with severe renal impairment. Monitor for toxicity and drug interactions.</p></div>
<div class="block dohp drugH1Div" id="F51129929"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Monitor for toxicity and drug interactions.</p></div>
<div class="block adr drugH1Div" id="F195148"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (13%), skin discoloration (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (20%), nausea (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration (74%; blue-green)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (16%), feeling hot (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (84%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort (4%), orthostatic dizziness (2%), presyncope (2%), syncope (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (5%), diaphoresis (2%), ecchymosis (2%), erythema of skin (2%), pallor (5%), pruritus (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (4%), diarrhea (2%), oral discomfort (2%), oral hypoesthesia (2%), oral paresthesia (9%), vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Discomfort at injection site (2%), infusion-site pain (6%), local discomfort (2%; limb)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (4%), chills (2%), headache (10%), malaise (2%), paresthesia (9%), sensation of cold (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (2%), back pain (2%), muscle spasm (2%), musculoskeletal pain (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (2%), flu-like symptoms (4%)</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, palpitations, swelling of extremities, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Papule of skin</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Flatulence, glossalgia, lower abdominal pain, tongue rash, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Induration at injection site, injection-site pruritus, swelling at injection site, urticaria at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, eye pruritus, ocular hyperemia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion, oropharyngeal pain, rhinorrhea, sneezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Ulcer (necrotic)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Phototoxicity (Maguire 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia (Vincer 1987), methemoglobinemia (McRobb 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (Vincer 1987)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Dewachter 2005), anaphylaxis (Giladi 2012)</p></div>
<div class="block coi drugH1Div" id="F195158"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to methylene blue or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Methylene blue (generic): Pregnancy; women who are or may become pregnant; intraspinal injection and SubQ injection</p>
<p style="text-indent:-2em;margin-left:2em;">Provayblue: Hypersensitivity to any other thiazine dye; patients with glucose-6-phosphate dehydrogenase deficiency (G6PD).</p></div>
<div class="block war drugH1Div" id="F195146"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant: If administering as a continuous infusion, ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Infuse via central line if possible; monitor IV site closely (Dumbarton 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Discontinue use and initiate supportive treatment if severe hypersensitivity reactions or anaphylaxis occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: At high doses or in patients with G6PD-deficiency and infants, methylene blue may catalyze the oxidation of ferrous iron in hemoglobin to ferric iron causing paradoxical methemoglobinemia and hemolysis; onset of anemia may be delayed 1or more days and may require red blood cell transfusions. Use the lowest effective number of doses during treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; monitor for drug toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustments may be needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cyanide-poisoned patients: Patients with cyanide toxicity may receive nitrites to induce methemoglobinemia. Methylene blue should <b>not</b> be used to reverse nitrite-induced methemoglobinemia in this scenario because methylene blue will release free cyanide from methemoglobin (Mokhlesi 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Use with caution in patients with G6PD deficiency (may result in severe hemolysis and anemia); use of Provayblue is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Inject slowly over a period of several minutes to prevent high local concentration from producing additional methemoglobin. Large IV doses produce nausea, abdominal and precordial pain, dizziness, headache, profuse sweating, mental confusion, and formation of methemoglobin. Do not inject subcutaneously or intrathecally.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Provayblue: If methemoglobinemia does not respond to 2 doses of methylene blue or if rebounds after a response, consider additional treatment options.</p>
<p style="text-indent:-2em;margin-left:4em;">• Enteral feedings: Methylene blue should not be added to enteral feeding products (Durfee 2006; Wessel 2005). Safety and efficacy have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Monitoring: Use methods other than pulse oximetry to assess oxygen saturation (presence of methylene blue in the blood may result in an underestimation of the oxygen saturation reading). A fall in the bispectral index has been reported following administration of methylene blue; use alternative methods for assessing the depth of anesthesia if administered during surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin and body fluid discoloration: May cause blue discoloration of the skin and body fluids.</p></div>
<div class="block foc drugH1Div" id="F195153"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ProvayBlue: 50 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/10 mL (10 mL); 1% (1 mL [DSC], 10 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ProvayBlue: 50 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/2 mL (2 mL)</p></div>
<div class="block geq drugH1Div" id="F195142"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F49198661"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (ProvayBlue Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/10 mL (per mL): $31.25</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867527"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (25 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (1 mL, 5 mL)</p></div>
<div class="block adm drugH1Div" id="F195155"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Administer undiluted by direct IV injection slowly over several minutes. If a prolonged or continuous infusion is employed, administration via central line is recommended due to the risk of extravasation injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22388329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22388329'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">ProvayBlue: Administer IV over 5 to 30 minutes; do not administer subcutaneously. May be diluted (in D5W <b>only</b>) prior to administration to avoid pain on injection.</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses (based on mechanism of extravasation injury) proximal to the injection site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Optimal treatments </i>
<i>for methylene blue extravasations are unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>): </i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Nitroglycerin 2% ointment (based on mechanism of extravasation injury):</i> Apply a 1-inch strip of topical nitroglycerin 2% ointment to the site of ischemia to cover the affected area; may repeat every 8 hours as necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Phentolamine:</i>
<b>SUBQ: </b>Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose IV through the infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide-induced encephalopathy (off-label use):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Methylene blue may be administered either undiluted as a slow IV push over at least 5 minutes or diluted and infused over 5 to 30 minutes. Consider concomitant dextrose administration, especially in patients who are hypoglycemic, to ensure efficacy of methylene blue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16391008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16391008'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Administer mixed in fruit juice to mask the taste (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16391008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16391008'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b> When used as a diagnostic aid (off label), spray or directly apply solution to the affected mucosa; methylene blue is used in conjunction with other preparatory methods (procedure-dependent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18178207','lexi-content-ref-24016362','lexi-content-ref-24639382','lexi-content-ref-19215918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18178207','lexi-content-ref-24016362','lexi-content-ref-24639382','lexi-content-ref-19215918'])">Ref</a></span>). When used for the treatment of onychomycosis (off label), apply to affected area and wait 3 minutes for the solution to soak in followed by photodynamic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30168611','lexi-content-ref-32890444','lexi-content-ref-24474123','lexi-content-ref-24502311','lexi-content-ref-24626676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30168611','lexi-content-ref-32890444','lexi-content-ref-24474123','lexi-content-ref-24502311','lexi-content-ref-24626676'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraparenchymal (off-label route):</b> When used for sentinel node mapping in breast cancer surgery (off label), administer as an injection either in a subareolar or peritumoral area directly into nodal tissue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28173818','lexi-content-ref-11469932','lexi-content-ref-12679308','lexi-content-ref-15720998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28173818','lexi-content-ref-11469932','lexi-content-ref-12679308','lexi-content-ref-15720998'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Do <b>NOT</b> administer subcutaneously or intrathecally.</p></div>
<div class="block admp drugH1Div" id="F52613301"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Administer IV; may be administered intraosseously if necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12845393','lexi-content-ref-9867898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12845393','lexi-content-ref-9867898'])">Ref</a></span>). <b>Do not inject intrathecally or subcutaneously.</b></p>
<p style="text-indent:-2em;margin-left:2em;">Provay blue (0.5% solution): Administer diluted (to lessen local pain) or undiluted over 5 to 30 minutes; if administered undiluted, follow with a flush (eg, 15 to 30 mL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Generic (1% solution): Administer undiluted or diluted by direct IV injection over 5 to 10 minutes; may follow with a flush (eg, 15 to 30 mL) to lessen local pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Apply dry warm compresses (based on mechanism of extravasation injury) proximal to the injection site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>). Initiate nitroglycerin (topical) antidote (See Management of Drug Extravasations for details).</p></div>
<div class="block use drugH1Div" id="F195154"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Methemoglobinemia (acquired):</b> Treatment of pediatric and adult patients with acquired methemoglobinemia.</p></div>
<div class="block off-label drugH1Div" id="F25469399"><span class="drugH1">Use: Off-Label: Adult</span><p>Chromoendoscopy (diagnostic aid); Ifosfamide-induced encephalopathy (treatment and secondary prophylaxis); Onychomycosis; Sentinel lymph node mapping in breast cancer surgery; Septic shock or other vasodilatory shock states; Shock, beta-blocker or calcium channel blocker overdose; Vasoplegia syndrome associated with cardiac surgery</p></div>
<div class="block mst drugH1Div" id="F195181"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Methylene Blue may be confused with VisionBlue</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Due to the potential for dosing errors between mg and mL of methylene blue, prescribing and dosing should only be expressed in terms of mg of methylene blue (and not as mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Due to potential toxicity (hemolytic anemia), do not use methylene blue to color enteral feedings to detect aspiration.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299700"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), UGT1A4, UGT1A9; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> Monoamine Oxidase</p></div>
<div class="block dri drugH1Div" id="F6221635"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Monoamine Oxidase Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apraclonidine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Apraclonidine. Monoamine Oxidase Inhibitors may increase the serum concentration of Apraclonidine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: Monoamine Oxidase Inhibitors may enhance the neurotoxic (central) effect of Atomoxetine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atropine (Ophthalmic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Atropine (Ophthalmic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: The use of benzhydrocodone is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation. If coadministration is required, use test doses and frequent titration of small benzhydrocodone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Monoamine Oxidase Inhibitors may increase the serum concentration of Betahistine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bezafibrate: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Bezafibrate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Blonanserin. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Ophthalmic): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Ophthalmic). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Topical). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Bromperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of BuPROPion. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Butorphanol: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Do not use carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbinoxamine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Carbinoxamine. Specifically, the anticholinergic effects of carbinoxamine may be enhanced and prolonged. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cerebrolysin: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clemastine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Clemastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Codeine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">COMT Inhibitors: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Avoid coadministration of COMT inhibitors and nonselective monoamine oxidase inhibitors (MAOIs) (eg, isocarboxazid, phenelzine, tranylcypromine, linezolid, methylene blue) whenever possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproheptadine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Cyproheptadine. Cyproheptadine may diminish the serotonergic effect of Monoamine Oxidase Inhibitors. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Deutetrabenazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Dexmethylphenidate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This may cause serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diamorphine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Diamorphine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diethylpropion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Diethylpropion. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dihydrocodeine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Consider avoiding use of dihydrocodeine while the patient is taking monoamine oxidase inhibitors (MAOIs) and for 2 weeks after MAOI discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diphenoxylate: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Domperidone. Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of Monoamine Oxidase Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOPamine: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of DOPamine.  Management: Initiate dopamine at no greater than one-tenth (1/10) of the usual dose in patients who are taking (or have taken within the last 2 to 3 weeks) monoamine oxidase inhibitors. Monitor for an exaggerated hypertensive response to dopamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxapram: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Doxapram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Doxylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Droxidopa: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Droxidopa. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROcodone. HYDROcodone may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.  Management: Consider alternatives to this combination when possible. If coadministration is required, use test doses, titrate small doses frequently, and monitor patients closely for evidence of serotonergic and opioid toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROmorphone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.  Management: Coadministration of hydromorphone and monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) is not recommended. If required, use test doses, titrate small doses frequently, and monitor for CNS and respitatory depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Indoramin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isometheptene: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Isometheptene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Monoamine Oxidase Inhibitors may enhance the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonordefrin: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Levonordefrin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: Methylene Blue may enhance the serotonergic effect of Linezolid. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Methylene Blue may enhance the serotonergic effect of Lithium. This could result in serotonin syndrome.  Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maprotiline: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meptazinol: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Meptazinol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaraminol: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Metaraminol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, monoamine oxidase inhibitors may enhance dopamine blockade, possible increasing the risk for neuroleptic malignant syndrome. Methotrimeprazine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Methylene Blue may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methyldopa: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Methyldopa. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Methylphenidate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Monoamine Oxidase Inhibitors may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Type B): May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Morphine (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalbuphine: Monoamine Oxidase Inhibitors may enhance the CNS depressant effect of Nalbuphine. Nalbuphine may enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Nalbuphine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.  Management: Use of nalbuphine is not recommended in patients taking MAOIs, or within 14 days of stopping MAOI therapy. If urgent nalbuphine use is needed, use test doses and frequent titration while monitoring blood pressure, CNS depression, and serotonergic toxicity<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefopam: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Nefopam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Norepinephrine: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Norepinephrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Normethadone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Normethadone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opicapone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opium: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Opium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: Use of oxycodone is not recommended for patients taking MAOIs or within 14 days of MAOI discontinuation. If combined, use test doses and frequent titration of small doses while monitoring blood pressure, CNS depression, and signs of serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyMORphone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pheniramine: May enhance the anticholinergic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pizotifen: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Pizotifen. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reboxetine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Remifentanil: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Remifentanil. Specifically, the risk for opioid toxicity (eg, respiratory depression) may be increased. Remifentanil may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.  Management: The use of remifentanil is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation. If coadministration is required, use test doses and titrate small doses of remifentanil frequently.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine. Monitor closely for paradoxical effects of reserpine (eg, excitation, hypertension).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): Methylene Blue may enhance the serotonergic effect of Serotonergic Opioids (High Risk). This could result in serotonin syndrome.  Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Monoamine Oxidase Inhibitors may increase the serum concentration of Serotonin 5-HT1D Receptor Agonists (Triptans).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sevoflurane: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Sevoflurane. Specifically, the risk of hemodynamic instability may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Solriamfetol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the risk for serotonin syndrome or opioid toxicities (eg, respiratory depression, coma) may be increased. Management: Sufentanil should not be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for serotonin syndrome and/or excessive CNS depression.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sulpiride. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tapentadol: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the additive effects of norepinephrine may lead to adverse cardiovascular effects. Tapentadol may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrozoline (Nasal): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tianeptine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tryptophan: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tyrosine: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Viloxazine: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308211"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use of some products may be contraindicated by the manufacturer in women who may become pregnant. In general, medications used as antidotes should take into consideration the health and prognosis of the female (Bailey 2003).</p></div>
<div class="block pri drugH1Div" id="F14079758"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use of some products may be contraindicated by the manufacturer in women who are pregnant. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey 2003).</p>
<p style="text-indent:0em;margin-top:2em;">Use during amniocentesis has shown evidence of fetal abnormalities (atresia of the ileum and jejunum, ileal occlusions); has been used orally without similar adverse events (Bailey 2003). Adverse events in the newborn following intra-amniotic injection near term also include hyperbilirubinemia, skin staining, and respiratory distress. In addition, hemolytic anemia, methemoglobinemia, and phototoxicity have been reported in neonates following in utero exposure (Burnakis 1995; Porat 1996; Vincer 1987). Based on studies in nonpregnant women, potential exposure to the fetus may be less when methylene blue is used for lymphatic mapping in breast cancer (Pruthi 2011). Monitor the newborn for adverse events if administered near term.</p></div>
<div class="block brc drugH1Div" id="F46732341"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if methylene blue is excreted in breast milk. One manufacturer recommends discontinuing breastfeeding during treatment and for up to 8 days after therapy is complete.</p></div>
<div class="block mop drugH1Div" id="F5210341"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Arterial or venous blood gases; cardiac monitoring (patients with pre-existing pulmonary and/or cardiac disease); CBC; methemoglobin levels (co-oximetry yields a direct and accurate measure of methemoglobin levels); pulse oximeter (will not provide accurate measurement of oxygenation when methemoglobin levels are &gt;35% or following methylene blue administration); renal function; signs and symptoms of methemoglobinemia such as pallor, cyanosis, nausea, muscle weakness, dizziness, confusion, agitation, dyspnea, and tachycardia; signs and symptoms of serotonin syndrome; transcutaneous O<sub>2</sub> saturation; monitor infusion site.</p></div>
<div class="block rer drugH1Div" id="F5210339"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobin levels (Ludlow 2020): <b>Note:</b> The level of methemoglobin is expressed as a percent of total hemoglobin affected.</p>
<p style="text-indent:-2em;margin-left:2em;">Generally asymptomatic.</p>
<p style="text-indent:-2em;margin-left:2em;">15% to 30%: Skin color changes (pale, gray, blue) most commonly seen on mucus membranes; headache, dyspnea, anxiety due to increasing hypoxia.</p>
<p style="text-indent:-2em;margin-left:2em;">30% to 50%: Weakness, tachypnea, palpitations, confusion.</p>
<p style="text-indent:-2em;margin-left:2em;">50% to 70%: Metabolic acidosis, cardiac arrhythmias, seizures, coma.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;70%: Usually fatal.</p></div>
<div class="block pha drugH1Div" id="F195145"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">In the treatment of methemoglobinemia, methylene blue hastens the conversion of methemoglobin to hemoglobin in low concentrations; however, it has the opposite effect at high concentrations by converting ferrous ion of reduced hemoglobin to ferric ion to form methemoglobin. In cyanide toxicity, methemoglobin combines with cyanide to form cyanomethemoglobin preventing the interference of cyanide with the cytochrome system.</p>
<p style="text-indent:0em;margin-top:2em;">In the treatment of vasoplegia syndrome, methylene blue may be able to restore vascular tone by a direct inhibitory effect on endothelial nitric oxide synthase (eNOS), and probably inducible NOS (iNOS), by oxidation of enzyme-bound ferrous iron. Methylene blue also blocks the formation of cyclic guanosine monophosphate (cGMP) by inhibiting the guanylate cyclase enzyme through binding to iron in the heme complex and subsequently reducing vasorelaxation (Lenglet 2011).</p></div>
<div class="block phk drugH1Div" id="F195157"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Reduction of methemoglobin: IV: 30 to 60 minutes (Clifton 2003)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: 53% to 97% (Clifton 2003)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 255 L ± 58 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 94%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Likely undergoes first pass metabolism or distribution; peripheral reduction to leukomethylene blue (Peter 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Not well-defined: 5 to 6.5 hours (Peter 2000); ProvayBlue: ~24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral: 1 to 2 hours (Peter 2000)); IV: 30 minutes (Clifton 2003)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: In bile, feces, and urine (~33% as leukomethylene blue) (Clifton 2003; Peter 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">ProvayBlue: Urine (~40% unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49939469"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Proveblue</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Methylthionium chloride proveblue | Metiblo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Azul de metileno</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Methylthioniniumchlorid proveblue</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Methylenblau vitis | Methylthioniniumchlorid proveblue</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Methylene Blue</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Methylthioninium chloride proveblue</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Proveblue</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Methylthioninium chloride proveblue</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Methylene Blue</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Methylthioninium chloride proveblue | Metilenkek pm</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Methylthioninium chloride proveblue</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Sam mb</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Metiltioninio bioindustria</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Methylene Blue | Proveblue</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Blumet | Proveblue</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Coloxyd | Methylenblau | Metiblo | Sam mb</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Coloxyd</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Methylene Blue</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Methylthioninium chloride proveblue</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Methylthioninium chloride proveblue</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Methylene Blue | Proveblue</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Coloxyd | Methylene Blue | Methylthioninium chloride proveblue | Metiblo | Metiltioninio cloruro bioindustria</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Methylene Blue | Provayblue</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Azul de metileno labesfal | Azul metileno | Cloreto de metiltionina proveblue | Proveblue</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Proveblue</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Methylenum Coeruleum</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Methylthioninium chloride proveblue</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Proveblue</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Methylthioninium chloride proveblue</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bleu de methylene</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Blumet</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Methylene Blue</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23334490">
<a name="23334490"></a>Aggarwal N, Kupfer Y, Seneviratne C, Tessler S. Methylene blue reverses recalcitrant shock in β-blocker and calcium channel blocker overdose. <i>BMJ Case Rep</i>. 2013;2013:bcr2012007402. doi:10.1136/bcr-2012-007402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/23334490/pubmed" id="23334490" target="_blank">23334490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30168611">
<a name="30168611"></a>Alberdi E, Gómez C. Efficiency of methylene blue-mediated photodynamic therapy vs intense pulsed light in the treatment of onychomycosis in the toenails. <i>Photodermatol Photoimmunol Photomed</i>. 2019;35(2):69-77. doi:10.1111/phpp.12420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/30168611/pubmed" id="30168611" target="_blank">30168611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32890444">
<a name="32890444"></a>Alberdi E, Gómez C. Methylene blue vs methyl aminolevulinate photodynamic therapy in the treatment of mild-to-moderate toenail onychomycosis: short- and medium-term effects. <i>Dermatol Ther</i>. 2020;33(6):e14280. doi: 10.1111/dth.14280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/32890444/pubmed" id="32890444" target="_blank">32890444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12891503">
<a name="12891503"></a>Albert M, Lessin MS, and Gilchrist BF, “Methylene Blue: Dangerous Dye for Neonates,” J Pediatr Surg, 2003, 38(8):1244-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/12891503/pubmed" id="12891503" target="_blank">12891503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34804706">
<a name="34804706"></a>Alyahya B, Alalshaikh A, Sabbahi G, Alnowiser M, Al-Mohawes M. Methylene blue infusion to treat severe dapsone-induced methemoglobinemia in a pediatric patient. <i>Cureus</i>. 2021;13(10):e18853. doi:10.7759/cureus.18853<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/34804706/pubmed" id="34804706" target="_blank">34804706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18178207">
<a name="18178207"></a>Areia M, Amaro P, Dinis-Ribeiro M, et al. External validation of a classification for methylene blue magnification chromoendoscopy in premalignant gastric lesions. <i>Gastrointest Endosc</i>. 2008;67(7):1011-1018. doi: 10.1016/j.gie.2007.08.044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/18178207/pubmed" id="18178207" target="_blank">18178207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B, "Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?" <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9605379">
<a name="9605379"></a>Bilgin H, Ozcan B, Bilgin T. Methemoglobinemia induced by methylene blue perturbation during laparoscopy. <i>Acta Anaesthesiol Scand</i>. 1998;42(5):594-595. doi:10.1111/j.1399-6576.1998.tb05173.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/9605379/pubmed" id="9605379" target="_blank">9605379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31711241">
<a name="31711241"></a>Bisschops R, East JE, Hassan C, et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2019. <i>Endoscopy</i>. 2019;51(12):1155-1179. doi:10.1055/a-1031-7657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/31711241/pubmed" id="31711241" target="_blank">31711241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32473398">
<a name="32473398"></a>Boltes Cecatto R, Siqueira de Magalhães L, Fernanda Setúbal Destro Rodrigues M, et al. Methylene blue mediated antimicrobial photodynamic therapy in clinical human studies: the state of the art. <i>Photodiagnosis Photodyn Ther</i>. 2020;31:101828. doi:10.1016/j.pdpdt.2020.101828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/32473398/pubmed" id="32473398" target="_blank">32473398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28173818">
<a name="28173818"></a>Brahma B, Putri RI, Karsono R, et al. The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy: a study from Dharmais Cancer Hospital. <i>World J Surg Oncol</i>. 2017;15(1):41. doi:10.1186/s12957-017-1113-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/28173818/pubmed" id="28173818" target="_blank">28173818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burnakis.1">
<a name="Burnakis.1"></a>Burnakis TG, “Inadvertent Substitution of Methylene Blue for Indigo Carmine to Detect Premature Rupture of Membranes,” <i>Hosp Pharm</i>, 1995, 30(4):336-8.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36225525">
<a name="36225525"></a>Cantrell C, Costers V, Wilson CC, Dudek CJ, Arnold JK. Refractory methemoglobinemia secondary to topical dapsone with subsequent autoimmune hemolytic anemia. <i>Cureus</i>. 2022;14(9):e28811. doi:10.7759/cureus.28811<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/36225525/pubmed" id="36225525" target="_blank">36225525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12845393">
<a name="12845393"></a>Clifton J 2nd and Leikin JB, “Methylene Blue,” <i>Am J Ther</i>, 2003, 10(4):289-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/12845393/pubmed" id="12845393" target="_blank">12845393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15923801">
<a name="15923801"></a>David KA and Picus J, “Evaluating Risk Factors for the Development of Ifosfamide Encephalopathy,” <i>Am J Clin Oncol</i>, 2005, 28(3):277-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/15923801/pubmed" id="15923801" target="_blank">15923801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2811676">
<a name="2811676"></a>Dawson AH and Whyte IM, “Management of Dapsone Poisoning Complicated by Methaemoglobinaemia,” <i>Med Toxicol Adverse Drug Exp</i>, 1989, 4(5):387-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/2811676/pubmed" id="2811676" target="_blank">2811676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353941">
<a name="23353941"></a>Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/23353941/pubmed" id="23353941" target="_blank">23353941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15976222">
<a name="15976222"></a>Dewachter P, Mouton-Faivre C, Tréchot P, Lleu JC, Mertes PM. Severe anaphylactic shock with methylene blue instillation. <i>Anesth Analg</i>. 2005;101(1):. doi:10.1213/01.ANE.0000153497.60047.80<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/15976222/pubmed" id="15976222" target="_blank">15976222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5044807">
<a name="5044807"></a>DiSanto AR and Wagner JG, “Pharmacokinetics of Highly Ionized Drugs II: Methylene Blue - Absorption, Metabolism, and Excretion in Man and Dog After Oral Administration,” <i>J Pharm Sci</i>, 1972, 61(7):1086-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/5044807/pubmed" id="5044807" target="_blank">5044807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8969734">
<a name="8969734"></a>Driscoll W, Thurin S, Carrion V, et al, "Effect of Methylene Blue on Refractory Neonatal Hypotension," <i>J Pediatr</i>, 1996, 129(6):904-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/8969734/pubmed" id="8969734" target="_blank">8969734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22388329">
<a name="22388329"></a>Dumbarton TC, Gorman SK, Minor S, et al. Local cutaneous necrosis secondary to a prolonged peripheral infusion of methylene blue in vasodilatory shock. <i>Ann Pharmacother</i>. 2012;46(3):e6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/22388329/pubmed" id="22388329" target="_blank">22388329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16439775">
<a name="16439775"></a>Durfee SM, Gallagher-Allred C, Pasquale JA, “Standards for Specialized Nutrition Support for Adult Residents of Long-Term Care Facilities,” <i>Nutr Clin Pract</i>, 2006, 21(1):96-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/16439775/pubmed" id="16439775" target="_blank">16439775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30606508">
<a name="30606508"></a>Feih JT, Rinka JRG, Zundel MT. Methylene blue monotherapy compared with combination therapy with hydroxocobalamin for the treatment of refractory vasoplegic syndrome: a retrospective cohort study. <i>J Cardiothorac Vasc Anesth</i>. 2019;33(5):1301-1307. doi:10.1053/j.jvca.2018.11.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/30606508/pubmed" id="30606508" target="_blank">30606508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24626676">
<a name="24626676"></a>Figueiredo Souza LW, Souza SV, Botelho AC. Distal and lateral toenail onychomycosis caused by Trichophyton rubrum: treatment with photodynamic therapy based on methylene blue dye. <i>An Bras Dermatol</i>. 2014b;89(1):184-186. doi:10.1590/abd1806-4841.20142197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/24626676/pubmed" id="24626676" target="_blank">24626676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24474123">
<a name="24474123"></a>Figueiredo Souza LW, Souza SV, Botelho AC. Endonyx toenail onychomycosis caused by Trichophyton rubrum: treatment with photodynamic therapy based on methylene blue dye. <i>An Bras Dermatol</i>. 2013;88(6):1019-1021. doi:10.1590/abd1806-4841.20132180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/24474123/pubmed" id="24474123" target="_blank">24474123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24502311">
<a name="24502311"></a>Figueiredo Souza LW, Souza SV, Botelho AC. Randomized controlled trial comparing photodynamic therapy based on methylene blue dye and fluconazole for toenail onychomycosis. <i>Dermatol Ther</i>. 2014a;27(1):43-47. doi:10.1111/dth.12042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/24502311/pubmed" id="24502311" target="_blank">24502311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32115360">
<a name="32115360"></a>Furnish C, Mueller SW, Kiser TH, Dufficy L, Sullivan B, Beyer JT. Hydroxocobalamin versus methylene blue for vasoplegic syndrome in cardiothoracic surgery: a retrospective cohort. <i>J Cardiothorac Vasc Anesth</i>. 2020;34(7):1763-1770. doi:10.1053/j.jvca.2020.01.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/32115360/pubmed" id="32115360" target="_blank">32115360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22743960">
<a name="22743960"></a>Giladi AM, Kasten SJ. Anaphylactic-like reaction to methylene blue: case report and review of perioperative hypersensitivity reactions. <i>Plast Reconstr Surg</i>. 2012;130(1):98e-105e. doi:10.1097/PRS.0b013e318254b2b8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/22743960/pubmed" id="22743960" target="_blank">22743960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16958960">
<a name="16958960"></a>Golshan M, Nakhlis F. Can methylene blue only be used in sentinel lymph node biopsy for breast cancer? <i>Breast J</i>. 2006;12(5):428-430. doi:10.1111/j.1075-122X.2006.00299.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/16958960/pubmed" id="16958960" target="_blank">16958960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344579">
<a name="26344579"></a>Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. <i>Br J Clin Pharmacol.</i> 2016;81(3):453-461. doi:10.1111/bcp.12763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/26344579/pubmed" id="26344579" target="_blank">26344579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6849836">
<a name="6849836"></a>Harvey JW and Keitt AS, “Studies of the Efficacy and Potential Hazards of Methylene Blue Therapy in Aniline-Induced Methaemoglobinaemia,” <i>Br J Haematol</i>, 1983, 54(1):29-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/6849836/pubmed" id="6849836" target="_blank">6849836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9867898">
<a name="9867898"></a>Herman MI, Chyka PA, Butler AY, Rieger SE. Methylene blue by intraosseous infusion for methemoglobinemia. <i>Ann Emerg Med</i>. 1999;33(1):111-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/9867898/pubmed" id="9867898" target="_blank">9867898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7795342">
<a name="7795342"></a>Hjelt K, Lund JT, Scherling B, et al. Methaemoglobinaemia among neonates in a neonatal intensive care unit. <i>Acta Paediatr</i>. 1995;84(4):365-370.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/7795342/pubmed" id="7795342" target="_blank">7795342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.1">
<a name="Howland.1"></a>Howland MA. Antidotes in depth. <i>Goldfrank's Toxicologic Emergencies</i>. 10th ed. Hoffman RS, Howland MA, Lewin NA, et al, eds. New York, NY: McGraw-Hill; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.2">
<a name="Howland.2"></a>Howland MA. Antidotes in depth: methylene blue. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies. </i>11th ed. McGraw-Hill; 2019:1713-1716.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36915146">
<a name="36915146"></a>Ibarra-Estrada M, Kattan E, Aguilera-González P, et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. <i>Crit Care</i>. 2023;27(1):110. doi:10.1186/s13054-023-04397-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/36915146/pubmed" id="36915146" target="_blank">36915146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24016362">
<a name="24016362"></a>Ichimasa K, Kudo SE, Mori Y, et al. Double staining with crystal violet and methylene blue is appropriate for colonic endocytoscopy: an in vivo prospective pilot study. <i>Dig Endosc</i>. 2014;26(3):403-408. doi: 10.1111/den.12164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/24016362/pubmed" id="24016362" target="_blank">24016362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jahns.1">
<a name="Jahns.1"></a>Jahns BE, Rynn KO, and Paloucek FP, “Interference of Methylene Blue (MthB) in the Determination of Whole Blood Methemoglobin (MtHgb) Concentrations,” <i>Vet Hum Toxicol</i>, 1994, 36:342.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32435102">
<a name="32435102"></a>Jaiswal A, Kumar M, Silver E. Extended continuous infusion of methylene blue for refractory septic shock. <i>Indian J Crit Care Med</i>. 2020;24(3):206-207. doi:10.5005/jp-journals-10071-23376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/32435102/pubmed" id="32435102" target="_blank">32435102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21546119">
<a name="21546119"></a>Jang DH, Nelson LS, Hoffman RS. Methylene blue in the treatment of refractory shock from an amlodipine overdose. <i>Ann Emerg Med</i>. 2011;58(6):565-567. doi:10.1016/j.annemergmed.2011.02.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/21546119/pubmed" id="21546119" target="_blank">21546119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20109575">
<a name="20109575"></a>Juffermans NP, Vervloet MG, Daemen-Gubbels CR, Binnekade JM, de Jong M, Groeneveld AB. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. <i>Nitric Oxide</i>. 2010;22(4):275-280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/20109575/pubmed" id="20109575" target="_blank">20109575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21360537">
<a name="21360537"></a>Kaklamanos IG, Birbas K, Syrigos K, Bonatsos VG, Bonatsos G. Prospective comparison of peritumoral and subareolar injection of blue dye alone, for identification of sentinel lymph nodes in patients with early stage breast cancer. <i>J Surg Oncol</i>. 2011;104(1):37-40. doi:10.1002/jso.21897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/21360537/pubmed" id="21360537" target="_blank">21360537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24639382">
<a name="24639382"></a>Kaminski MF, Hassan C, Bisschops R, et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. <i>Endoscopy</i>. 2014;46(5):435-449. doi: 10.1055/s-0034-1365348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/24639382/pubmed" id="24639382" target="_blank">24639382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28078984">
<a name="28078984"></a>Khan M, Paul S, Farooq S, Oo TH, Ramshesh P, Jain N. Rasburicase-induced methemoglobinemia in a patient with glucose-6- phosphate dehydrogenase deficiency. <i>Curr Drug Saf</i>. 2017;12(1):13-18. doi:10.2174/1574886312666170111151246<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/28078984/pubmed" id="28078984" target="_blank">28078984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12671882">
<a name="12671882"></a>Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. <i>Gastroenterology</i>. 2003;124(4):880-888. doi:10.1053/gast.2003.50146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/12671882/pubmed" id="12671882" target="_blank">12671882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17383417">
<a name="17383417"></a>Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. <i>Gastroenterology</i>. 2007;132(3):874-882. doi:10.1053/j.gastro.2007.01.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/17383417/pubmed" id="17383417" target="_blank">17383417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11588440">
<a name="11588440"></a>Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. <i>Crit Care Med</i>. 2001;29(10):1860-1867. doi:10.1097/00003246-200110000-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/11588440/pubmed" id="11588440" target="_blank">11588440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22103871">
<a name="22103871"></a>Lenglet S, Mach F, and Montecucco F, Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery. <i>Expert Rev Cardiovas Ther</i>. 2011;9(12):1519-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/22103871/pubmed" id="22103871" target="_blank">22103871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14759425">
<a name="14759425"></a>Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. <i>Ann Thorac Surg</i>. 2004;77(2):496-499. doi:10.1016/S0003-4975(03)01510-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/14759425/pubmed" id="14759425" target="_blank">14759425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12830064">
<a name="12830064"></a>Leyh RG, Kofidis T, Strüber M, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? <i>J Thorac Cardiovasc Surg</i>. 2003;125(6):1426-1431. doi:10.1016/s0022-5223(02)73284-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/12830064/pubmed" id="12830064" target="_blank">12830064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30235340">
<a name="30235340"></a>Li J, Chen X, Qi M, Li Y. Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: a systematic review and meta-analysis. <i>PLoS One</i>. 2018;13(9):e0204364. doi:10.1371/journal.pone.0204364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/30235340/pubmed" id="30235340" target="_blank">30235340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14707556">
<a name="14707556"></a>López A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. <i>Crit Care Med</i>. 2004;32(1):21-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/14707556/pubmed" id="14707556" target="_blank">14707556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ludlow.1">
<a name="Ludlow.1"></a>Ludlow JT, Wilkerson RG, Nappe TM. Methemoglobinemia. <i>StatPearls [Internet]</i>. <a href="https://www.ncbi.nlm.nih.gov/books/NBK537317/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK537317/</a>. Published September 4, 2020. StatPearls Publishing. Accessed January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36705345">
<a name="36705345"></a>Luis-Silva F, Menegueti MG, Sato L, et al. Effect of methylene blue on hemodynamic response in the early phase of septic shock: a case series. <i>Medicine (Baltimore)</i>. 2023;102(4):e32743. doi:10.1097/MD.0000000000032743<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/36705345/pubmed" id="36705345" target="_blank">36705345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28398918">
<a name="28398918"></a>Maguire CA, Sharma A, Alarcon L, et al. Histological features of methylene blue-induced phototoxicity administered in the context of parathyroid surgery. <i>Am J Dermatopathol</i>. 2017;39(8):e110-e115. doi:10.1097/DAD.0000000000000856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/28398918/pubmed" id="28398918" target="_blank">28398918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16214982">
<a name="16214982"></a>Maloney JP, Ryan TA, Brasel KJ, et al, “Food Dye Use in Enteral Feedings: A Review and a Call for a Moratorium,” <i>Nutr Clin Pract</i>, 2002, 17(3):169-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/16214982/pubmed" id="16214982" target="_blank">16214982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16790616">
<a name="16790616"></a>Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. <i>Anesth Analg</i>. 2006;103(1):2-8, table of contents. doi:10.1213/01.ane.0000221261.25310.fe<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/16790616/pubmed" id="16790616" target="_blank">16790616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18853835">
<a name="18853835"></a>McRobb CM, Holt DW. Methylene blue-induced methemoglobinemia during cardiopulmonary bypass? A case report and literature review. <i>J Extra Corpor Technol</i>. 2008;40(3):206-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/18853835/pubmed" id="18853835" target="_blank">18853835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28551045">
<a name="28551045"></a>Mehaffey JH, Johnston LE, Hawkins RB, et al. Methylene blue for vasoplegic syndrome after cardiac operation: early administration improves survival. <i>Ann Thorac Surg</i>. 2017;104(1):36-41. doi:10.1016/j.athoracsur.2017.02.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/28551045/pubmed" id="28551045" target="_blank">28551045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12500513">
<a name="12500513"></a>Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. <i>Anaesth Intensive Care</i>. 2002;30(6):755-762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/12500513/pubmed" id="12500513" target="_blank">12500513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BPI.1">
<a name="BPI.1"></a>Methylene blue [prescribing information]. Largo, FL: BPI Labs LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, Corbridge TC. Adult toxicology in critical care: Part II: specific poisonings. <i>Chest</i>. 2003;123(3):897-922. doi:10.1378/chest.123.3.897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35761204">
<a name="35761204"></a>Naoum EE, Dalia AA, Roberts RJ, Devine LT, Ortoleva J. Methylene blue for vasodilatory shock in the intensive care unit: a retrospective, observational study. <i>BMC Anesthesiol</i>. 2022;22(1):199. doi:10.1186/s12871-022-01739-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/35761204/pubmed" id="35761204" target="_blank">35761204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19215918">
<a name="19215918"></a>Ngamruengphong S, Sharma VK, Das A. Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett's esophagus: a meta-analysis. <i>Gastrointest Endosc</i>. 2009;69(6):1021-1028. doi: 10.1016/j.gie.2008.06.056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/19215918/pubmed" id="19215918" target="_blank">19215918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25247756">
<a name="25247756"></a>Omar S, Zedan A, Nugent K. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. <i>Am J Med Sci</i>. 2015;349(1):80-88. doi: 10.1097/MAJ.0000000000000341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/25247756/pubmed" id="25247756" target="_blank">25247756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917073">
<a name="31917073"></a>Ortoleva J, Shapeton A, Vanneman M, Dalia AA. Vasoplegia during cardiopulmonary bypass: current literature and rescue therapy options. <i>J Cardiothorac Vasc Anesth</i>. 2020;34(10):2766-2775. doi:10.1053/j.jvca.2019.12.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/31917073/pubmed" id="31917073" target="_blank">31917073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20575634">
<a name="20575634"></a>Paciullo CA, McMahon Horner D, Hatton KW, Flynn JD. Methylene blue for the treatment of septic shock. <i>Pharmacotherapy</i>. 2010;30(7):702-715. doi: 10.1592/phco.30.7.702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/20575634/pubmed" id="20575634" target="_blank">20575634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16391008">
<a name="16391008"></a>Patel PN. Methylene blue for management of ifosfamide-induced encephalopathy. <i>Ann Pharmacother</i>. 2006;40(2):299-303. doi:10.1345/aph.1G114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/16391008/pubmed" id="16391008" target="_blank">16391008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10646879">
<a name="10646879"></a>Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. <i>Br J Cancer</i>. 2000;82(2):291-294. doi:10.1054/bjoc.1999.0917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/10646879/pubmed" id="10646879" target="_blank">10646879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10952480">
<a name="10952480"></a>Peter C, Hongwan D, Küpfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. <i>Eur J Clin Pharmacol</i>. 2000;56(3):247-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/10952480/pubmed" id="10952480" target="_blank">10952480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8628613">
<a name="8628613"></a>Porat R, Gilbert S, Magilner D. Methylene blue-induced phototoxicity: an unrecognized complication. <i>Pediatrics</i>. 1996;97(5):717-721.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/8628613/pubmed" id="8628613" target="_blank">8628613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32020043">
<a name="32020043"></a>Porizka M, Kopecky P, Dvorakova H, et al. Methylene blue administration in patients with refractory distributive shock – a retrospective study. <i>Sci Rep</i>. 2020;10(1):1828. doi:10.1038/s41598-020-58828-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/32020043/pubmed" id="32020043" target="_blank">32020043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7532559">
<a name="7532559"></a>Preiser JC, Lejeune P, Roman A, et al, “Methylene Blue Administration in Septic Shock: A Clinical Trial,” <i>Crit Care Med</i>, 1995, 23(2):259-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/7532559/pubmed" id="7532559" target="_blank">7532559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Provayblue.1">
<a name="Provayblue.1"></a>Provayblue (methylene blue) [prescribing information]. Shirley, NY: American Regent Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21167367">
<a name="21167367"></a>Pruthi S, Haakenson C, Brost BC, et al. Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer-implications for use in pregnancy. <i>Am J Surg</i>. 2011;201(1):70-75. doi:10.1016/j.amjsurg.2009.03.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/21167367/pubmed" id="21167367" target="_blank">21167367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16143539">
<a name="16143539"></a>Shanmugam G, "Vasoplegic Syndrome -- the Role of Methylene Blue," <i>Eur J Cardiothorac Surg</i>, 2005, 28(5):705-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/16143539/pubmed" id="16143539" target="_blank">16143539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32339671">
<a name="32339671"></a>Shen JJ, Jemec GBE, Arendrup MC, Saunte DML. Photodynamic therapy treatment of superficial fungal infections: a systematic review. <i>Photodiagnosis Photodyn Ther</i>. 2020;31:101774. doi:10.1016/j.pdpdt.2020.101774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/32339671/pubmed" id="32339671" target="_blank">32339671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8130867">
<a name="8130867"></a>Sills M and Zinkham W, “Methylene Blue-Induced Heinz Body Hemolytic Anemia,” <i>Arch Pediatr Adolesc Med</i>, 1994, 148(3):306-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/8130867/pubmed" id="8130867" target="_blank">8130867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11469932">
<a name="11469932"></a>Simmons RM, Smith SM, Osborne MP. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. <i>Breast J</i>. 2001;7(3):181-183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/11469932/pubmed" id="11469932" target="_blank">11469932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12679308">
<a name="12679308"></a>Simmons R, Thevarajah S, Brennan MB, Christos P, Osborne M. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. <i>Ann Surg Oncol</i>. 2003;10(3):242-247.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/12679308/pubmed" id="12679308" target="_blank">12679308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy.</i> 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25835504">
<a name="25835504"></a>Tardivo JP, Wainwright M, Baptista M. Small scale trial of photodynamic treatment of onychomycosis in São Paulo. <i>J Photochem Photobiol B</i>. 2015;150:66-68. doi:10.1016/j.jphotobiol.2015.03.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/25835504/pubmed" id="25835504" target="_blank">25835504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15720998">
<a name="15720998"></a>Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. <i>Am J Surg</i>. 2005;189(2):236-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/15720998/pubmed" id="15720998" target="_blank">15720998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14570094">
<a name="14570094"></a>Turner AR, Duong CD, Good DJ. Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. <i>Clin Oncol (R Coll Radiol)</i>. 2003;15(7):435-439. doi:10.1016/s0936-6555(03)00114-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/14570094/pubmed" id="14570094" target="_blank">14570094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3815215">
<a name="3815215"></a>Vincer MJ, Allen AC, Evans JR, Nwaesei C, Stinson DA. Methylene-blue-induced hemolytic anemia in a neonate. <i>CMAJ</i>. 1987;136(5):503-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/3815215/pubmed" id="3815215" target="_blank">3815215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23972738">
<a name="23972738"></a>Weiner MM, Lin HM, Danforth D, Rao S, Hosseinian L, Fischer GW. Methylene blue is associated with poor outcomes in vasoplegic shock. <i>J Cardiothorac Vasc Anesth</i>. 2013;27(6):1233-1238. doi: 10.1053/j.jvca.2013.02.026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/23972738/pubmed" id="23972738" target="_blank">23972738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16207652">
<a name="16207652"></a>Wessel J, Balint J, Crill C, et al. Standards for specialized nutrition support: hospitalized pediatric patients<i>Nutr Clin Pract</i>, 2005, 20(1):103-116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/16207652/pubmed" id="16207652" target="_blank">16207652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10533013">
<a name="10533013"></a>Wright RO, Lewander WJ, and Woolf AD, “Methemoglobinemia: Etiology, Pharmacology, and Clinical Management,” <i>Ann Emerg Med</i>, 1999, 34(5):646-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/10533013/pubmed" id="10533013" target="_blank">10533013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36237547">
<a name="36237547"></a>Zhao CC, Zhai YJ, Hu ZJ, Huo Y, Li ZQ, Zhu GJ. Efficacy and safety of methylene blue in patients with vasodilatory shock: a systematic review and meta-analysis. <i>Front Med (Lausanne)</i>. 2022;9:950596. doi:10.3389/fmed.2022.950596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/36237547/pubmed" id="36237547" target="_blank">36237547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26108709">
<a name="26108709"></a>Zuckerman M, Greller HA, Babu KM. A review of the toxicologic implications of obesity. <i>J Med Toxicol</i>. 2015;11(3):342-354. doi:10.1007/s13181-015-0488-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/26108709/pubmed" id="26108709" target="_blank">26108709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7700329">
<a name="7700329"></a>Zulian GB, Tullen E, and Maton B, “Methylene Blue for Ifosfamide-Associated Encephalopathy,” <i>N Engl J Med</i>, 1995, 332(18):1239-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylene-blue-drug-information/abstract-text/7700329/pubmed" id="7700329" target="_blank">7700329</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9636 Version 329.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
